<DOC>
	<DOCNO>NCT01816789</DOCNO>
	<brief_summary>This randomize controlled trial design carry comparison new AMH ( Anti-Müllerian Hormone ) -based individualize treatment ( use nomogram ) wide accept age-based strategy . The main objective trial ass whether individualized FSH start dose increase rate woman adequate ovarian response term retrieve oocyte ( optimal number retrieve oocyte : 8-14 ) .</brief_summary>
	<brief_title>Age Versus Ovarian Reserve Markers Based Therapy IVF ( IVF ) /Intracytoplasmic Sperm Injection ( ICSI ) Cycles</brief_title>
	<detailed_description>Before clinician adopt model routine clinical practice , accuracy model independently evaluate population different one model elaborate . External validation model therefore crucial ass generalizability population . In present RCT new AMH-based individualize treatment compare wide accept age-based strategy . Primary endpoint : The percentage woman appropriate number ( n=8-14 ) retrieve oocyte IVF/ICSI cycle . Secondary endpoint : 1 . Serum E2 level r-hCG day 2 . Serum P level r-hCG day 3 . Number grow follicle ( ≥11mm ) r-hCG day 4 . Number large ( ≥ 17 mm ) ovarian follicle r-hCG day 5 . Total r-FSH dose employ 6 . Treatment duration 7 . Rate woman dose adjustment 8 . Number cancel cycle poor hyper-response 9 . Fertilization rate 10 . Embryos obtain 11 . Implantation rate 12 . Biochemical pregnancy rate 13 . Clinical pregnancy rate 14 . OHSS rate</detailed_description>
	<mesh_term>Buserelin</mesh_term>
	<criteria>first second IVF/ICSI attempt ( second one 6 month first one ) ; regular menstrual cycle ( 2533 day ) ; female age ≤ 40 ; day 3 FSH ≤ 15IU/L ; treatment long GnRH agonist protocol ( buserelin ) +rFSH ; BMI : &gt; 18 ≤ 25 kg/m2 ; presence ovary . irregular cycle , anovulatory infertility , endometriosis IIIIV stage AFS , use adjunctive therapy stimulation , evidence PCO status , previous ovarian surgery , presence ovarian cyst , history PID , use hormonal contraception previous 3 month , know metabolic endocrinological disease , AMH level &lt; 1 &gt; 4.0 ng/ml</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Starting dose</keyword>
	<keyword>rFSH</keyword>
	<keyword>control</keyword>
	<keyword>ovarian</keyword>
	<keyword>stimulation</keyword>
	<keyword>IVF/ICSI</keyword>
	<keyword>cycle</keyword>
</DOC>